Our Team
BRIM Biotechnology brings together experts across science, engineering, and technology disciplines to deliver a more efficient, less costly, drug development process. Our talented team has forged decades worth of strong global connections and experience. We operate based on a virtual biotechnology model, integrating our expert R&D operation team in Taiwan with our skilled overseas scientific team. We have years of experience working in technological and pharmaceutical development, regulatory affairs, and marketing and IP, with expertise across the field of innovative drug development, including pre-clinical toxicology, clinical pharmacology, and management. We harness the power of our team’s expertise in translational science to deliver a difference for patients.
Translational Science Expertise
BRIM R&D Operational Team
BRIM R&D
Operational Team
BRIM R&D
Operational Team
Pre-clinical & Toxicology
Dr. Frank Lee
Chief Strategy Officer & BRIM Cayman Chairman
Dr. Frank Lee
Chief Strategy Officer & BRIM Cayman Chairman
Dr. Carl Alden
Senior Fellow
Dr. Carl Alden
Senior Fellow
Previously Vice President at Millennium
Held various roles at Searle, Monsanto, Pharmacia & P&G
Served as Editor of Veterinary Pathology and Toxicology Pathology and President at Society of Toxicology Pathologist
Clinical Pharmacology & Clinical Management
Wen Chyi Shyu, PhD
CEO
Wen Chyi Shyu, PhD
CEO
Vice President of Global Drug Metabolism and Pharmacokinetics at Takeda
30+ years of experience in drug metabolism and pharmacokinetics
Haishan Jang, PhD, MBA
Vice Chairman, CGS (Chief Global Strategist)
Haishan Jang, PhD, MBA
Vice Chairman, CGS (Chief Global Strategist)
Dr. Conrad Tou
Senior Fellow
Dr. Conrad Tou
Senior Fellow
30+ years of experience in biotech and large pharmaormer director at Hollis-Eden pharma
Held several positions at Sanofi-Winthrop and AstraZeneca, with expertise in statistics and data management
CMC & Pharmaceutical Development
Dr. Wayne Liaw
Senior Fellow
Dr. Wayne Liaw
Senior Fellow
Previously held Senior Director positions at Otonomy and Optimer
Former director at Hollis-Eden pharma
Regulation
Su Lin
VP of Operation
Su Lin
VP of Operation
Marketing and IP
Dr. Chyau Liang
Senior Fellow
Dr. Chyau Liang
Senior Fellow
Previously Partner at Osha Liang LLP
Former Professor at the University of Texas-Houston School of Medicine
SABs & KOLs
Dr. Pan-Chyr Yang
Scientific Board Member
Dr. Pan-Chyr Yang
Scientific Board Member
Academician at Academia Sinica and Professor at National Taiwan University
Previously President of National Taiwan University
Editor-in-Chief of MicroRNA and Lung Cancer: Targets and Therapy
Dr. Robert Ruffolo
Scientific Board Member
Dr. Robert Ruffolo
Scientific Board Member
Previously President of R&D and Corporate Senior Vice President of Wyeth Pharmaceuticals
Senior Vice President and Director of Research at SmithKline Beecham Pharmaceuticals
Chairman of the Cardiovascular Research Committee at Eli Lilly & Company
Dr. Eliot Lazar
Scientific Board Member
Dr. Eliot Lazar
Scientific Board Member
CEO at elCON Medical Consulting
Previously held Assistant Professor positions at the State University of NY and the University of Rochester
Leadership Team
Wen Chyi Shyu, PhD
CEO
With more than three decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and management expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in drug metabolism to pharmacokinetics (DMPK) ranges from pre-clinical research discovery to clinical drug development and extended to life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.Wen Chyi brings to BRIM extensive industry experience and a passion for driving innovation in the drug discovery and development process. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee and Treasury of the New England Drug Metabolism Discussion Group (NEDMDG) to identify and improve the drug discovery process and to shorten the study turnaround time.Wen Chyi has a passion for developing people. Through training and motivation, research scientists can be developed into successful pharmaceutical executives to build international and multi-disciplinary teams. She, as an example, has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Wen Chyi Shyu, PhD
CEO
With more than three decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and management expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in drug metabolism to pharmacokinetics (DMPK) ranges from pre-clinical research discovery to clinical drug development and extended to life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.Wen Chyi brings to BRIM extensive industry experience and a passion for driving innovation in the drug discovery and development process. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee and Treasury of the New England Drug Metabolism Discussion Group (NEDMDG) to identify and improve the drug discovery process and to shorten the study turnaround time.Wen Chyi has a passion for developing people. Through training and motivation, research scientists can be developed into successful pharmaceutical executives to build international and multi-disciplinary teams. She, as an example, has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Mei-Hui Kuo, MS
COO
Ms. Mei-Hui Kuo has over 35 years of experience in the biotechnology pharmaceutical industry. She was the founding COO of BRIM and now has returned to work with the new management team to reach BRIM′s operation goals. In her career, she has served successfully in many key positions including COO at Senhwa Biosciences, VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment.Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.
Mei-Hui Kuo, MS
COO
Ms. Mei-Hui Kuo has over 35 years of experience in the biotechnology pharmaceutical industry. She was the founding COO of BRIM and now has returned to work with the new management team to reach BRIM′s operation goals. In her career, she has served successfully in many key positions including COO at Senhwa Biosciences, VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment.Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.
Haishan Jang, PhD, MBA
Vice Chairman, CGS (Chief Global Strategist)
Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Haishan Jang, PhD, MBA
Vice Chairman, CGS (Chief Global Strategist)
Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Frank W. Lee, PhD
CSO
Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy.In addition to holding a Board position at BRIM, Frank sits on the board at Foresee Pharmaceuticals in Taiwan. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs.Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
Frank W. Lee, PhD
CSO
Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy.In addition to holding a Board position at BRIM, Frank sits on the board at Foresee Pharmaceuticals in Taiwan. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs.Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
Erin Chang, MS
VP of Portfolio Development
Erin Chang graduated from the Graduate Institute of Toxicology at the National Taiwan University and has more than 15 years’ of experience in new drug development and project management. She previously worked at TTY Biopharm and Taiwan Liposome Company, where she participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs.
Erin Chang, MS
VP of Portfolio Development
Erin Chang graduated from the Graduate Institute of Toxicology at the National Taiwan University and has more than 15 years’ of experience in new drug development and project management. She previously worked at TTY Biopharm and Taiwan Liposome Company, where she participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs.
Su Lin, MS
VP of Government Regulation
Su Lin gained her Master of Science degree in Hospital Pharmacy Administration at Temple University, Graduate School of Pharmacy. She has nearly 20 years of experience in the pharmaceutical industry, specifically in regulatory affairs and labeling. She has worked in global pharmaceutical companies such as Intercept, Regeneron Pharmaceuticals, Bristol-Myers Squibb, and Wyeth Collegeville.
Su Lin, MS
VP of Government Regulation
Su Lin gained her Master of Science degree in Hospital Pharmacy Administration at Temple University, Graduate School of Pharmacy. She has nearly 20 years of experience in the pharmaceutical industry, specifically in regulatory affairs and labeling. She has worked in global pharmaceutical companies such as Intercept, Regeneron Pharmaceuticals, Bristol-Myers Squibb, and Wyeth Collegeville.
Yi-Chun Maria Chen, PhD
VP of Business Development
Dr. Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. Maria received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.
Yi-Chun Maria Chen, PhD
VP of Business Development
Dr. Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. Maria received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.
Amanda Yen
VP of Finance
Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.
Amanda Yen
VP of Finance
Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.
Senior Scientific Team
Carl Alden, PhD
Sr. Toxicology Fellow
Carl Alden, PhD
Sr. Toxicology Fellow
Conrad Tou, PhD
Sr. Biostatistic Fellow
Conrad Tou, PhD
Sr. Biostatistic Fellow
Chyau Liang, PhD
Sr. IP Fellow
Chyau Liang, PhD
Sr. IP Fellow
Wayne Liaw, PhD
Sr. Formulation Fellow
Wayne Liaw, PhD
Sr. Formulation Fellow